First patient enrolled in study of BioLineRx's celiac treatment

• BioLineRx (BLRX +1.8%) enrolls the first patient in a Phase 1/2 study of BL-7010 in celiac disease.
• Results from the study — which is designed to "assess the safety of single and repeated ascending doses in well-controlled celiac patients" — are due in mid-2014. (PR)